Skip to main content

Table 1 Characteristics of study population, by use of pegfilgrasim prophylaxis in cycle 1

From: Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study

 

Commercial

Medicare

No Pegfilgrastim Use

Pegfilgrastim Use

No Pegfilgrastim Use

Pegfilgrastim Use

(n = 16,512)

(n = 34,266)

(n = 20,195)

(n = 50,842)

Patient

 Age (years)

  Mean (SD)

54.3 (10.2)

56.2 (10.9)

72.3 (5.4)

73.6 (5.9)

 Female, N (%)

14,623 (89%)

29,995 (88%)

16,604 (82%)

37,811 (74%)

 Chronic Comorbidities, N (%)

  Cardiovascular Disease

1403 (8%)

3851 (11%)

6124 (30%)

16,979 (33%)

  Diabetes

1750 (11%)

4211 (12%)

5217 (26%)

13,022 (26%)

  Liver Disease

621 (4%)

1386 (4%)

731 (4%)

1999 (4%)

  Lung Disease

1290 (8%)

3157 (9%)

3033 (15%)

8053 (16%)

  Renal Disease

311 (2%)

855 (2%)

1523 (8%)

4598 (9%)

  Osteoarthritis

1382 (8%)

3361 (10%)

4534 (22%)

11,620 (23%)

  Rheumatoid Disease

236 (1%)

561 (2%)

670 (3%)

1798 (4%)

  Thyroid Disorder

2105 (13%)

4569 (13%)

4470 (22%)

11,723 (23%)

 Body Weight and Nutritional Status, N (%)

  Obese

1244 (8%)

2688 (8%)

1715 (8%)

3959 (8%)

  Malnutrition

71 (0%)

289 (1%)

414 (2%)

1517 (3%)

 Proxies for Health Status, N (%)

  Hospice Care

38 (0%)

120 (0%)

572 (3%)

2037 (4%)

  SNF

100 (1%)

244 (1%)

926 (5%)

2194 (4%)

  Hospice or SNF

136 (1%)

352 (1%)

1400 (7%)

3962 (8%)

 Proxies for Physical Function, N (%)

  Use of Hospital Bed

26 (0%)

78 (0%)

162 (1%)

476 (1%)

  Use of Supplemental Oxygen

259 (2%)

681 (2%)

810 (4%)

2285 (4%)

  Use of Walking Aid

192 (1%)

506 (1%)

772 (4%)

2455 (5%)

  Use of Wheel Chair

53 (0%)

136 (0%)

378 (2%)

997 (2%)

  Any of Above

487 (3%)

1256 (4%)

1807 (9%)

5268 (10%)

 Use of Immunosuppressive Drugs, N (%)

5273 (32%)

11,113 (32%)

6612 (33%)

17,145 (34%)

 Other Conditions/Events Prior to Chemotherapy, N (%)

  Anemia

1896 (11%)

4721 (14%)

6025 (30%)

17,970 (35%)

  Neutropenia

290 (2%)

1295 (4%)

948 (5%)

4738 (9%)

  Infection

7902 (48%)

17,204 (50%)

11,545 (57%)

29,868 (59%)

  Recent Surgery (prior 90 days)

13,881 (84%)

28,100 (82%)

13,024 (64%)

30,427 (60%)

  History of Hospitalization for Any Reason

4549 (28%)

9985 (29%)

7739 (38%)

20,374 (40%)

  History of Chemotherapy

866 (5%)

2127 (6%)

1623 (8%)

4755 (9%)

  History of Radiation Therapy

910 (6%)

1955 (6%)

883 (4%)

2140 (4%)

Cancer and Chemotherapy, N (%)

 Breast Cancer

13,261 (80%)

26,622 (78%)

13,305 (66%)

25,675 (50%)

  TAC

389 (2%)

4179 (12%)

235 (1%)

1857 (4%)

  TC

8793 (53%)

14,918 (44%)

8032 (40%)

19,493 (38%)

  TCH

4079 (25%)

7525 (22%)

5038 (25%)

4325 (9%)

 NHL — CHOP±R

3251 (20%)

7644 (22%)

6890 (34%)

25,167 (50%)

 Year of Chemotherapy (Commercial), N (%)

  2010–2011

7150 (43%)

13,308 (39%)

–

–

  2012–2013

6108 (37%)

13,108 (38%)

–

–

  2014–2015

3254 (20%)

7850 (23%)

–

–

 Year of Chemotherapy (Medicare), N (%)

  2007–2009

–

–

6268 (31%)

12,984 (26%)

  2010–2012

–

–

8615 (43%)

21,004 (41%)

  2013–2015

–

–

5312 (26%)

16,854 (33%)

  1. TAC docetaxel + doxorubicin + cyclophosphamide, TC docetaxel + cyclophosphamide, TCH docetaxel + cyclophosphamide + trastuzumab, CHOP cyclophosphamide + doxorubicin + vincristine + prednisone with rituximab (R)